| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000021760 |
| Receipt No. | R000025093 |
| Official scientific title of the study | Multicenter retrospective observational study on the treatment of Medication-Related Osteonecrosis of the Jaw(MRONJ) |
| Date of disclosure of the study information | 2016/04/05 |
| Last modified on | 2016/04/03 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Multicenter retrospective observational study on the treatment of Medication-Related Osteonecrosis of the Jaw(MRONJ) | |
| Title of the study (Brief title) | Multicenter retrospective observational study on the treatment of MRONJ | |
| Region |
|
|
| Condition | ||
| Condition | Medication-Related Osteonecrosis pf the Jaw(MRONJ) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Elucidation of Prognostic facors in the treatment and course of MRONJ |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Prognosis after medical treatment MRONJ |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patient from January 1, 2009 until December 31, 2015 and medical treatment the MRONJ in participating centers, and there is a medical record for the survey items | |||
| Key exclusion criteria | Below, it shall be applicable even one excluded.
1. Patient record was insufficient on the survey items. 2. Patinets who had the intention of nonparticipation. 3. patients principal investigator has determined to be inappropriate as a subject. |
|||
| Target sample size | 250 | |||
| Research contact person | |
| Name of lead principal investigator | Saki Hayashida |
| Organization | Nagasaki University Graduate School of Biomedical Sciences |
| Division name | Department of Clinical Oral Oncology |
| Address | 1-7-1, Sakamoto, Nagasaki 852-8588, Japan |
| TEL | 095-819-7698 |
| sakihaya@nagasaki-u.ac.jp | |
| Public contact | |
| Name of contact person | Saki Hayashida |
| Organization | Nagasaki University Graduate School of Biomedical Sciences |
| Division name | Department of Clinical Oral Oncology |
| Address | 1-7-1, Sakamoto, Nagasaki 852-8588, Japan |
| TEL | 095-819-7698 |
| Homepage URL | |
| sakihaya@nagasaki-u.ac.jp | |
| Sponsor | |
| Institute | Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | 1. Methods
Survey item:age, sex, underlying disease,medical history, type and duration of BMA use, risk factors, BMA of preoperative washout, preoperative blood test data(WBC, BUN, Cr, AST, ALT, TP, Alb,ect.), operative procedure, course, X-ray and CT photos of before and after surgery 2. Statistical analysis Perform a single logistic regression analysis for each factor. To calculate the odds ratios and 95% confidence interval and P value. The factors that influence the development of events from P <0.05, and past research as explanatory variables, perform a multivariate logistic regression analysis. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000025093 |